Hidradenitis Suppurativa or Acne Inversa (HS) is a chronic, inflammatory, recurrent integumentary disease, with periods of exacerbation, related to metabolic comorbidities, affecting the well-being, quality of life and mental health of patients, in addition to negatively influencing oral health and women’s health levels as well. It often presents little responsiveness to conventional dermatological treatments. With the aim of estimating the biopsychosocial and economic impact on patients’ lives, a qualitative systematic review was planned. The results were similar to clinical practice and also with several qualitative reviews, i.e. low efficiency. It was observed few studies of good quality, low number randomized clinical trials, and quantitative systematic review, as well. Thus, (HS) has not yet been mapped into the Evidence-Based paradigm and justifies the low assertiveness of therapeutic modalities conventionally instituted to date, as most of them are still structured empirically. Under this circumstance, and due experience and achieviments with these patients at the Instituto da Pele/Departamento de Dermatologia da Escola Paulista de Medicina da Universidade Federal de São Paulo/UNIFESP/Brazil (Monson 2019) [1], was decided to expand spectrum the research, and to add Oral and Systemic Health and Women’s Health, simultaneously to the conventionally studied biopsycho-social parameters. The results were not surprising and revealed the importance of expanding scientific research on HS. As implications for practice, we sought to qualitatively map knowledge to help organize a comprehensive minimum protocol for HS care beyond the conventionally adopted parameters, and include ways of measuring the quality levels of oral health and women’s health with aimed at the quality of life of these patients. Thus, a more realistic and assertive management could be given to the target population, as well as the adoption of complementary therapeutic modalities (according to WHO parameters), and applied in a co-intervention regime, to control these new sets of comorbidities that have been considered by the present study with the objective of increasing the levels of efficacy, effectiveness and safety by Good Clinical Practices. Even though we still do not have the methodological conditions to establish Guidelines for HS, we at least strive to make care for these patients increasingly humanized and inclusive